title: Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial.
authors.forename: S Mitchell
authors.initials: SM
authors.lastname: Harman
authors.forename: Eliot A
authors.initials: EA
authors.lastname: Brinton
authors.forename: Frederick
authors.initials: F
authors.lastname: Naftolin
authors.forename: George R
authors.initials: GR
authors.lastname: Merriam
authors.forename: Marcelle I
authors.initials: MI
authors.lastname: Cedars
authors.forename: Ruth G
authors.initials: RG
authors.lastname: Freeman
authors.forename: Nanette
authors.initials: N
authors.lastname: Santoro
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003627:Data Interpretation, Statistical; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects*; D017698:Postmenopause / Q000187:drug effects*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D004966:Estrogens, Conjugated (USP); D017258:Medroxyprogesterone Acetate